文献速递慢阻肺

度普利尤单抗对慢阻肺合并2型炎症患者健康相关生活质量及呼吸道症状的影响:BOREAS与NOTUS研究

Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS.
PubMed 文献 · Chest · 2025-01-31

本汇总分析纳入两项3期试验中接受三联治疗的慢阻肺合并2型炎症患者,随机接受度普利尤单抗300 mg每2周一次(n=938)或安慰剂(n=936)治疗52周。第52周时,度普利尤单抗较安慰剂显著改善SGRQ总分(最小二乘均值差-3.4,95%CI -5.0至-1.8,P<.0001)和E-RS:COPD总分(-0.9,95%CI -1.4至-0.4,P=.0006),各领域评分也观察到类似改善。

要点

  • 度普利尤单抗可改善慢阻肺合并2型炎症患者的健康相关生活质量(SGRQ)和呼吸道症状(E-RS:COPD)。
  • SGRQ总分改善-3.4(95%CI -5.0至-1.8),E-RS:COPD总分改善-0.9(95%CI -1.4至-0.4)。
  • 症状、活动、 impacts各领域及呼吸困难等领域评分均见改善。

核心结论

  • 在慢阻肺合并2型炎症患者中,度普利尤单抗可改善SGRQ和E-RS:COPD总分及各领域评分。

研究设计与样本

  • 两项3期试验的汇总分析,患者接受三联治疗,随机1:1接受度普利尤单抗300 mg(n=938)或安慰剂(n=936)每2周一次治疗52周。
  • 共1660例患者达到第52周(每组n=830)。

主要发现

  • 第52周时,度普利尤单抗较安慰剂降低SGRQ总分,最小二乘均值差-3.4(95%CI -5.0至-1.8;P<.0001)。
  • 第52周时,度普利尤单抗较安慰剂降低E-RS:COPD总分,最小二乘均值差-0.9(95%CI -1.4至-0.4;P=.0006)。
  • SGRQ症状领域评分改善-3.5(95%CI -5.5至-1.5),活动领域-4.0(95%CI -5.9至-2.1), Impacts领域-2.9(95%CI -4.6至-1.1)。
  • E-RS:COPD呼吸困难领域评分改善-0.6(95%CI -0.8至-0.3),咳嗽咳痰领域-0.2(95%CI -0.3至0.0),胸部症状领域-0.1(95%CI -0.3至0.0)。

临床怎么用

  • 对于接受三联治疗仍存在症状负担的慢阻肺合并2型炎症患者,可考虑加用度普利尤单抗以改善生活质量和呼吸道症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient-reported outcomes should be considered alongside clinical assessments to guide therapy for COPD. RESEARCH QUESTION: Does add-on dupilumab treatment improve health-related quality of life and respiratory symptoms in patients with COPD and type 2 inflammation? STUDY DESIGN AND METHODS: In this pooled analysis of two phase 3 trials, patients with COPD and type 2 inflammation receiving triple therapy were randomized 1:1 to receive dupilumab 300 mg (n = 938) or placebo (n = 936) every 2 weeks for 52 weeks. Quality of life and respiratory symptom severity were measured by change from baseline to week 52 in St. George's Respiratory Questionnaire (SGRQ; total [0-100 units, lower scores indicating better quality of life] and domain scores for symptoms, activity, and impacts) and Evaluating Respiratory Symptoms in COPD (E-RS:COPD; total [0-40 units, lower scores meaning less severe respiratory symptoms] and domain scores for breathlessness, cough and sputum, and chest symptoms) scores. RESULTS: In total, 1,660 patients reached week 52 (n = 830 in each treatment arm). At week 52, dupilumab vs placebo reduced SGRQ and E-RS:COPD total scores by least squares mean differences (95% CI) of -3.4 (-5.0 to -1.8; P < .0001) and -0.9 (-1.4 to -0.4; P = .0006), respectively. Similar reductions were observed across SGRQ domain scores of symptoms (-3.5 [-5.5 to -1.5]), activity (-4.0 [-5.9 to -2.1]), and impacts (-2.9 [-4.6 to -1.1]), and E-RS:COPD domain scores of breathlessness (-0.6 [-0.8 to -0.3]), cough and sputum (-0.2 [-0.3 to 0.0]), and chest symptoms (-0.1 [-0.3 to 0.0]). INTERPRETATION: Dupilumab exhibited improvements in SGRQ and E-RS:COPD total and domain scores in patients with COPD and type 2 inflammation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifiers; Numbers: NCT03930732 and NCT04456673; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Bhatt SP, Rabe KF, Hanania NA, et al. Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS. Chest. 2025. PMID: 39894389. doi:10.1016/j.chest.2025.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。